<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T14:42:18Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/53345" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/53345</identifier><datestamp>2026-04-15T10:06:51Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_36358</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Ladiges, Warren C</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Mazzola, Jordan Margaret</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-08-01T22:13:13Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025-08-01</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2025</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">Mazzola_washington_0250O_28508.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1773/53345</dim:field>
   <dim:field mdschema="dc" element="description">Thesis (Master&amp;apos;s)--University of Washington, 2025</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Age-related cognitive decline (ARCD) is a neurodegenerative process accompanied with memory loss, neuronal dysfunction, and more such as chronic inflammation and increased cellular senescence. It impacts a large percentage of the aging population, increases in prevalence with age, and is a known risk factor for more severe neurodegenerative diseases such as Alzheimer’s Disease. Currently, there are no known treatments to stop or reverse the process of ARCD which presents a clear knowledge gap and opportunity to investigate potential gerotherapeutics. Glycyl-L-histidyl-L-lysine (GHK) is a naturally occurring peptide that forms complexes with copper (II) to improve wound healing and improve several age-related skin changes. Several studies have connected treatment of GHK-Cu to improvement of several hallmarks of aging via the inhibition of TGF-β and provides reasoning for exploring GHK-Cu as a potential gerotherapeutic. To test this potential, a short-term five-day treatment of GHK-Cu in middle-aged mice was performed. C57BL/6 mice, 20 to 22-months of age, were administered an intraperitoneal (IP) injection of GHK-Cu daily for five days. Cognitive function was assessed on the fifth day of treatment via a spatial navigation learning task. Several markers in the brain were assessed via immunohistochemistry (IHC) of the hippocampus and cerebellum. These markers include TGF-β1, GFAP, and phosphorylated-SMAD2 to assess the TGF-β pathway, synaptophysin and PSD95 to assess pre- and post-synaptic function, and p21 and MCP-1 to investigate cellular senescence and inflammation respectively. Aging pathways and gene regulation of GHK-Cu was investigated by RNA sequencing of the hippocampus. Results suggest improvement of cognitive function in male mice treated with GHK-Cu across several aspects including learning and memory shown via a behavioral assay, and decreased inflammation and cellular senescence. Results also revealed strong sex-dependent phenotypes within this treatment pathway as female mice treated with GHK-Cu showed less cognitive rescue when compared to male mice. This study provides support that a short-term treatment of GHK-Cu can positively impact cognitive function in middle-aged mice in a sex-dependent manner and provides potential pathways of interest for further investigation into the sex-dependent phenotypes observed. This provides support for GHK-Cu’s potential as a gerotherapeutic and progress in alleviating the negative effects of ARCD.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights">none</dim:field>
   <dim:field mdschema="dc" element="subject">age-related cognitive decline</dim:field>
   <dim:field mdschema="dc" element="subject">aging</dim:field>
   <dim:field mdschema="dc" element="subject">geropathology</dim:field>
   <dim:field mdschema="dc" element="subject">GHK-Cu</dim:field>
   <dim:field mdschema="dc" element="subject">immunohistochemistry</dim:field>
   <dim:field mdschema="dc" element="subject">resilience</dim:field>
   <dim:field mdschema="dc" element="subject">Aging</dim:field>
   <dim:field mdschema="dc" element="subject">Gerontology</dim:field>
   <dim:field mdschema="dc" element="subject">Neurosciences</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Comparative medicine</dim:field>
   <dim:field mdschema="dc" element="title">Short-term treatment of mice with GHK peptide enhances resilience to age-related cognitive decline</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms">Restrict to UW for 1 year -- then make Open Access</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="lift">2026-08-01T22:13:13Z</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>